Lemon Balm

Metadata

Approved Indications

Commission E (Germany)

• Approved: Nervous sleeping disorders; functional GI complaints

ESCOP

• Approved: Tenseness, restlessness, irritability; symptomatic treatment of digestive disorders such as minor spasms
• Approved (topical): Cold sores (herpes labialis)

EMA/HMPC (2013)

• Traditional use: Relief of mild symptoms of mental stress and to aid sleep
• Traditional use: Relief of mild gastrointestinal complaints including bloating and flatulence
• Well-established use (cutaneous): Treatment of herpes labialis (specific concentrated aqueous dry extract, 70:1)

Agreement/Disagreement

All bodies agree on the internal dual indication of nervous/mental stress and GI complaints. The topical herpes indication is recognized by ESCOP and granted “well-established use” by EMA (based on clinical data), making it the strongest-evidenced indication for lemon balm. Commission E does not specifically address the topical antiviral use in its original monograph.

Conditions Treated

Primary (Moderate Evidence)

• Mild symptoms of mental stress / anxiety — Traditional internal use
• Sleep disturbance — Particularly when related to nervous tension
• Herpes labialis (cold sores) — Topical application of concentrated aqueous extract. This is the best-evidenced indication.

Secondary (Moderate Evidence)

• Mild GI complaints — Bloating, flatulence, mild spasms (traditional use)
• Cognitive function / Alertness — Emerging evidence for improved mood, calmness, and mathematical processing speed

Emerging (Limited Evidence)

• Alzheimer’s disease / Cognitive decline — Based on AChE inhibition properties [NEEDS-RESEARCH]
• Heart palpitations — One study showed 1000 mg/day reduced palpitations
• Emotional distress and poor sleep — Phospholipid carrier-based extract in healthy adults

Mechanism of Action

Lemon balm has a multi-target pharmacological profile spanning three major neurotransmitter systems:

1. GABAergic System

• GABA transaminase inhibition: Rosmarinic acid inhibits GABA transaminase, the enzyme that degrades GABA. This leads to accumulation of GABA levels in the brain, producing anxiolytic and sedative effects.
• This mechanism is distinct from direct GABA-A receptor binding (as in benzodiazepines or valerian) and represents a complementary pathway to increasing GABAergic tone.

2. Cholinergic System

• Acetylcholinesterase (AChE) inhibition: Both rosmarinic acid and certain terpenoid constituents inhibit AChE, the enzyme that breaks down acetylcholine.
• Rosmarinic acid shows ~40% AChE inhibition at 100 microg/mL in vitro.
• This mechanism is directly relevant to cognitive enhancement and is the same target as prescription Alzheimer’s drugs (donepezil, rivastigmine, galantamine).
• Nicotinic and muscarinic receptor binding: Some affinity for cholinergic receptors demonstrated in vitro.

3. Serotonergic System

• Modulation of serotonergic pathways contributing to anxiolytic and mood effects.

4. Antiviral Mechanism (Topical)

• Rosmarinic acid and other polyphenols interfere with viral attachment and entry of herpes simplex virus (HSV-1 and HSV-2) to host cells.
• Direct virucidal activity demonstrated in vitro against HSV-1 and HSV-2.

Key Active Constituent: Rosmarinic Acid

Rosmarinic acid is the principal bioactive compound, responsible for:

• GABA transaminase inhibition (anxiolytic)
• AChE inhibition (cognitive)
• Antiviral activity (topical herpes)
• Antioxidant and anti-inflammatory properties

Clinical Evidence Summary

Anxiety and Mood

Kennedy et al. (2004) — Dose-Finding Study

• 20 healthy volunteers
• 600 mg standardized extract: Improved mood, increased calmness and alertness
• 300 mg standardized extract: Increased mathematical processing speed with no reduction in accuracy
• Both doses modulated mood and cognitive performance within 1-3 hours of administration

Scholey et al. (2014) — Cyracos Extract

• Stressed individuals; 600 mg/day Cyracos for 15 days
• Significant reductions in anxiety (-18%) and insomnia (-42%)

Ranjbar et al. (2023) — Phospholipid Carrier Extract

• Healthy adults with emotional distress and poor sleep
• Randomized, double-blind, placebo-controlled
• Significant improvements in emotional distress and sleep quality
• [Source: Frontiers in Pharmacology 2023]

Systematic Review and Meta-Analysis (Ghazizadeh et al., 2021)

• Reviewed clinical trials on depression, anxiety, and sleep
• Conclusion: Oral lemon balm may help reduce anxiety and depression and improve sleep
• Caveat: Heterogeneity across studies; more high-quality RCTs needed
• [Source: PubMed 34449930]

Topical Herpes (Strongest Clinical Evidence)

Koytchev et al. (1999) — Herpes Labialis RCT

• Design: Randomized, double-blind, placebo-controlled
• n = 66 patients with herpes simplex
• Melissa cream (70:1 concentrated aqueous extract) applied 4 times/day for 5 days
• Result: Significant reduction in symptom scores. Combined symptom score on day 2 showed significant advantage over placebo. Earlier healing.
• This is the study that supports EMA’s “well-established use” designation for the topical herpes indication.

In Vitro Evidence

• Melissa officinalis extract inhibits HSV-1 and HSV-2 replication
• Mechanism: Interference with virus attachment to host cells
• Also active against acyclovir-resistant HSV strains [NEEDS-RESEARCH for clinical significance]

Cognitive Effects

Akhondzadeh et al. (2003) — Alzheimer’s RCT

• n = 42 patients with mild-moderate Alzheimer’s disease
• Melissa extract 60 drops/day (standardized, containing citral) vs. placebo, 4 months
• Result: Significant improvement in cognition (ADAS-cog) and reduction in agitation
• Limitation: Small sample; single trial

Heart Palpitations

• 1000 mg/day lemon balm capsules for 2 weeks significantly decreased heart palpitations in adults
• Mechanism likely related to autonomic nervous system modulation

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to lemon balm or other Lamiaceae
• No other absolute contraindications

Drug Interactions

• Theoretical: Additive sedation with CNS depressants
• Thyroid medications: In vitro evidence suggests Melissa may inhibit TSH binding to thyroid receptors and interfere with thyroid function. Clinical significance at standard doses is uncertain but caution in hypothyroid patients taking levothyroxine is advised. [UNCERTAIN]
• Glaucoma medications: Theoretical concern based on intraocular pressure effects seen in animal studies
• Overall: No significant drug interactions documented in clinical use at recommended doses

Side Effects

• Generally very safe and well-tolerated
• Reported (rare): Nausea, abdominal pain, dizziness, wheezing
• Topical: Contact dermatitis (very rare)

Pregnancy and Lactation

• Pregnancy: Insufficient data. Traditional use suggests safety, but no formal studies. Not recommended by EMA during pregnancy.
• Lactation: Traditionally used to promote milk flow (galactagogue), but no formal safety data. Not recommended by EMA during lactation.

Clinical Dosage

Internal Use (Anxiety/Sleep)

• Dried leaf (tea): 1.5-4.5 g per 150 mL water, 1-3 times daily
• Standardized extract: 300-600 mg/day (e.g., Cyracos: 600 mg/day)
• Tincture (1:5, 45% ethanol): 2-6 mL, 1-3 times daily
• Fluid extract (1:1): 2-4 mL, 3 times daily

Topical Use (Herpes)

• Concentrated aqueous extract cream (70:1): Apply thin layer 2-4 times daily at first sign of symptoms, continue for 5-14 days
• Product example: Lomaherpan/LomaProtect cream

EMA/HMPC Recommendations

• Traditional use: 1.5-4.5 g comminuted herbal substance as tea, 2-3 times daily
• Duration: If symptoms persist after 2 weeks, consult a physician

Sources

• EMA/HMPC Final Assessment Report on Melissa officinalis L., folium
• EMA/HMPC Final Community Herbal Monograph on Melissa officinalis L., folium
• Commission E Monograph: Melissa leaf
• ESCOP Monograph: Melissae folium
• Kennedy DO et al. Modulation of mood and cognitive performance following acute administration of Melissa officinalis. Pharmacol Biochem Behav. 2004
• Koytchev R et al. Balm mint extract for the topical treatment of recurring herpes labialis. Phytomedicine. 1999;6(4):225-230
• Akhondzadeh S et al. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74(7):863-866
• Ghazizadeh J et al. Effects of Melissa officinalis on depression and anxiety. PubMed 34449930
• Inhibition of HSV-2 by Melissa: PubMed 19023806
• AChE inhibition: PubMed 19070498
• Clinical efficacy review (2024): PMC11510126
• Examine.com: Lemon Balm
• LiverTox: Lemon Balm (NCBI NBK600583)

Connections

• GABAergic mechanism (GABA transaminase inhibition) is a different pathway than valerian (GABA-A allosteric modulation): see Valerian
• AChE inhibition connects to ginkgo’s cognitive indication: see Ginkgo
• Often combined with valerian for sleep: see Valerian
• Topical antiviral use is unique in this herb collection
• Compare anxiolytic evidence with stronger options: Lavender, Kava